Meeting
2018 ASCO Annual Meeting
RET-rearranged lung cancers: Immunophenotype and response to immunotherapy.
Authors
Joshua K. Sabari
Memorial Sloan Kettering Cancer Center, New York, NY
Joshua K. Sabari , Michael David Offin , Stephanie L Wu , Ai Ni , Darragh Halpenny , Joseph Montecalvo , Dazhi Liu , Terry K. Pak , Kathryn Cecilia Arbour , Wei-Chu Victoria Lai , Matthew David Hellmann , Gregory J. Riely , Mark G. Kris , Charles M. Rudin , Natasha Rekhtman , Bob T. Li , Josiah David Land , Alexander E. Drilon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9034)
DOI
10.1200/JCO.2018.36.15_suppl.9034
Abstract #
9034
Poster Bd #
357
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC.
First Author: Emily Castellanos
Poster
2023 ASCO Annual Meeting
A phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation.
First Author: Colin R Lindsay
Poster
2022 ASCO Annual Meeting
Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥ 50%) lung cancer.
First Author: Arielle Elkrief
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates